单、双标记基因筛选的转人乳铁蛋白基因供核细胞生产克隆山羊效率的比较

为比较两种筛选标记基因生产转人乳铁蛋白(hLF)基因克隆山羊的效率,利用单(新霉素抗性基因,Neor)、双(新霉素抗性和绿色荧光蛋白基因,Neor/GFP)标记基因筛选转基因的供核细胞,并制作体细胞核移植转基因山羊。山羊胎儿成纤维细胞电转染单标记基因表达载体(pBLC14)或双标记基因表达载体(pAPLM),分别有58.8%(20/34)和86.7%(26/30)的抗性细胞株检测到外源基因;转染pAPLM的细胞传代培养后,仅有20%(6/30)株细胞在传代中所有细胞均能观察到荧光;分别以pBLC14和pAPLM的细胞株作为供核细胞进行体细胞核移植,共获得806枚重构胚胎,胚胎移植受体后35 d、60 d妊娠率分别为53.8%、26.9%和39.1%、21.7%,最终分别产下5只(1.9%)和7只(1.4%)克隆山羊;经PCR及Southern blotting检测,所有出生山羊均整合有外源基因。结果显示,以单、双标记基因筛选供核细胞,其重构胚融合率、怀孕率和克隆动物出生率差异不显著(P>0.05),Neor/GFP双标记基因能准确、有效地用于转基因供核细胞筛选。同时,结果也表明Neor/GFP双标记基因转染的体细胞作为供核细胞对体细胞克隆效率未出现不利影响。     

转录激活因子样效应物核酸酶介导的山羊β-乳球蛋白基因敲除和人乳铁蛋白基因定点整合

为了敲除山羊乳中致敏源β-乳球蛋白(BLG)基因,同时在BLG基因座定点整合人乳铁蛋白(hLF)基因。首先针对山羊BLG第3外显子识别位点设计了1对特异性TALEN-3-L/R质粒对;同时,构建了含有1个HSV-TK负筛选基因的hLF基因打靶载体BLC14-TK。TALENs质粒对转染山羊胎儿成纤维细胞,2μg/m L嘌呤霉素筛选3 d,PCR扩增产物测序来验证其切割DNA活性。打靶载体BLC14-TK与TALEN-3-L/R质粒对共转染山羊胎儿成纤维细胞,经700μg/m L G418和2μg/m L GCV共筛选药物抗性细胞株;通过整合检测和同源重组检测来筛选hLF基因打靶细胞株;BLG~–/hLF~+打靶细胞株作为供核细胞进行山羊体细胞核移植。结果为:TALEN-3-L/R致突变率为25%-30%;获得BLG~–/hLF~+打靶细胞6株;共制作重构胚胎335枚,移植受体山羊23只,B超检测到30-35 d的妊娠受体9只(妊娠率39.1%),其中1只50日龄克隆胎儿验证为BLG~–/hLF~+基因型。以上结果表明获得BLG基因座定点整合hLF基因的基因打靶山羊是可行的,为培育羊乳中含低致敏原和富含hLF的山羊新品系奠定了基础。     

tPA/gGH双基因转染山羊乳腺上皮细胞表达分析

人组织纤溶酶原激活剂(tissue-type plasminogen activator,tPA)是一种被广泛应用于临床的溶栓药物。双基因共整合入生物体内能够产生协同作用,从而提高目的基因的表达水平。但是目前,利用gGH基因与tPA基因共整合以期提高tPA表达水平的相关研究较少。为筛选获得tPA高表达的tPA/gGH双基因整合的单克隆转基因山羊乳腺上皮细胞株,本研究以β-casein基因作为调控序列,构建乳腺特异性表达载体PCL25/gGH,并通过电转染将tPA和gGH双基因共转染山羊乳腺上皮细胞;通过G418筛选获得抗性细胞株,经PCR检测获得转基因单克隆细胞株;利用催乳素诱导tPA表达,收集48 h后细胞诱导液进行ELISA()和Western blotting检测并分析其tPA表达水平。结果表明,共获得142株抗性单克隆细胞,其中有53株tPA单基因整合细胞株,34株tPA/gGH双基因整合细胞株,双基因整合率达23.9%(34/142)。共检测出29株细胞能够表达tPA,其中单基因表达细胞为12株,表达率为22.6%(12/53);双基因表达细胞为17株,表达率为50.0%(17/34);且单基因细胞表达tPA含量为7.5~52.0μg/mL,而双基因细胞表达tPA含量为40~360μg/mL,明显高于单基因表达水平。本研究通过电转染的方式成功获得了tPA/gGH双基因整合的单克隆山羊乳腺上皮细胞株,并证明双基因整合的细胞株表达tPA水平明显提高,为后期制备高表达转基因山羊奠定了基础。     

由成年转基因山羊体细胞而来的克隆山羊

在已经获得的乳腺特异性表达人促红细胞生成素 (rhEPO)成年转基因山羊 (Caprahircus)的基础上 ,取其耳尖成纤维细胞和卵巢颗粒细胞 ,进行体外传代培养 ,然后将这种培养的转基因山羊的体细胞移入去核的处于第Ⅱ次减数分裂中期的卵母细胞中 ,并进行电融合 ,构建重构胚胎 ,重构胚胎在体内培养 6d ,再将发育至囊胚或桑椹胚的重构胚胎移入同步情期的寄母羊子宫内。结果 ,有 2只寄母羊妊娠并最终产下 2只成活的克隆山羊。她们分别来自同一成年母羊的耳尖成纤维细胞和卵巢颗粒细胞。克隆羊经PCR RFLP图谱分析显示 :以克隆羊组织DNA为模板的PCR产物与相应的提供体细胞的基因羊的PCR产物的酶切图谱完全一致 ;并且经PCR对外源hEPO基因检测表明 2只克隆山羊均携带hEPO外源基因。由此证明获得了转基因成年体细胞的克隆山羊     

转基因克隆奶山羊大量生产重组人的抗凝血酶Ⅲ蛋白质(rhATⅢ)

利用转基因克隆奶山羊乳腺生物反应器大量生产重组人的抗凝血酶Ⅲ(rhATⅢ)蛋白质.其中包括:筛选出人的抗凝血酶Ⅲ蛋白基因的cDNA序列;利用山羊的β-酪蛋白基因的启动区,终止信号和Enterokinase蛋白酶酶切DNA序列,构建在乳腺中特异表达rhATⅢ的表达栽体.同时在转基因载体的末端连接一个新酶素筛选基因(Neomycin).再以细胞转染、G418筛选和体细胞核移植(动物克隆)等过程,最后获得含有人的抗凝血酶Ⅲ基因的转基因克隆奶山羊.我们共获得了5个原代转基因公羊.第一只克隆羊在出生后78 d死亡,解剖表明:羊的肺部和肾脏等器官有异常.其它克隆公羊经过与崂山种母羊交配,得到转基因后代,其中两个原代转基因羊的后代母羊已成熟、所获得的奶经蛋白质电泳证明:转基因克隆羊后代奶中含有约60 kD大小的rhATⅢ糖蛋白;经Elisa检测表明:在奶中含有大量活性的rhATⅢ,在来源于两个不同克隆公羊的后代母羊奶中的rhATⅢ含量分别为0.4mg/L和3 g/L.此研究证明:转基因奶山羊可以大量地生产具有很高活性的rhATⅢ.用这种方法生产的rhATⅢ通过蛋白质提纯,制成注射针剂,将可用于人的抗凝血酶Ⅲ缺乏症的治疗、预防血栓和重大手术过程中的止血的作用等.     

转基因克隆奶山羊大量生产重组人的抗凝血酶III蛋白质(rhATIII)

利用转基因克隆奶山羊乳腺生物反应器大量生产重组人的抗凝血酶III(rhATIII)蛋白质。其中包括: 筛选出人的抗凝血酶Ⅲ蛋白基因的cDNA序列; 利用山羊的b－酪蛋白基因的启动区, 终止信号和Enterokinase蛋白酶酶切DNA序列, 构建在乳腺中特异表达rhATⅢ的表达载体。同时在转基因载体的末端连接一个新酶素筛选基因(Neomycin)。再以细胞转染、G418筛选和体细胞核移植(动物克隆)等过程, 最后获得含有人的抗凝血酶Ⅲ基因的转基因克隆奶山羊。我们共获得了5个原代转基因公羊。第一只克隆羊在出生后78 d死亡, 解剖表明: 羊的肺部和肾脏等器官有异常。其它克隆公羊经过与崂山种母羊交配, 得到转基因后代, 其中两个原代转基因羊的后代母羊已成熟、所获得的奶经蛋白质电泳证明: 转基因克隆羊后代奶中含有约60 kD大小的rhATⅢ糖蛋白; 经Elisa检测表明: 在奶中含有大量活性的rhATⅢ, 在来源于两个不同克隆公羊的后代母羊奶中的rhATⅢ含量分别为0.4 mg/L和3 g/L。此研究证明: 转基因奶山羊可以大量地生产具有很高活性的rhATⅢ。用这种方法生产的rhATⅢ通过蛋白质提纯, 制成注射针剂, 将可用于人的抗凝血酶III缺乏症的治疗、预防血栓和重大手术过程中的止血的作用等。     

转基因克隆奶山羊大量生产重组人的抗凝血酶III蛋白质(rhATIII)

利用转基因克隆奶山羊乳腺生物反应器大量生产重组人的抗凝血酶III(rhATIII)蛋白质。其中包括: 筛选出人的抗凝血酶Ⅲ蛋白基因的cDNA序列; 利用山羊的b－酪蛋白基因的启动区, 终止信号和Enterokinase蛋白酶酶切DNA序列, 构建在乳腺中特异表达rhATⅢ的表达载体。同时在转基因载体的末端连接一个新酶素筛选基因(Neomycin)。再以细胞转染、G418筛选和体细胞核移植(动物克隆)等过程, 最后获得含有人的抗凝血酶Ⅲ基因的转基因克隆奶山羊。我们共获得了5个原代转基因公羊。第一只克隆羊在出生后78 d死亡, 解剖表明: 羊的肺部和肾脏等器官有异常。其它克隆公羊经过与崂山种母羊交配, 得到转基因后代, 其中两个原代转基因羊的后代母羊已成熟、所获得的奶经蛋白质电泳证明: 转基因克隆羊后代奶中含有约60 kD大小的rhATⅢ糖蛋白; 经Elisa检测表明: 在奶中含有大量活性的rhATⅢ, 在来源于两个不同克隆公羊的后代母羊奶中的rhATⅢ含量分别为0.4 mg/L和3 g/L。此研究证明: 转基因奶山羊可以大量地生产具有很高活性的rhATⅢ。用这种方法生产的rhATⅢ通过蛋白质提纯, 制成注射针剂, 将可用于人的抗凝血酶III缺乏症的治疗、预防血栓和重大手术过程中的止血的作用等。     

整合人lactoferrin基因的山羊体细胞支持核移植克隆胚的体外发育

克隆了人lactoferrin基因和山羊[[beta]]-casein基因5′端调控区, 构建了人lactoferrin的乳腺表达载体, 并将该载体利用脂质体介导转染了奶山羊胎儿成纤维细胞, 获得了稳定整合人lactoferrin基因的转基因体细胞克隆17个, 其中PCR和Southern Blot检测阳性的细胞克隆14个, 阳性率82.4%。以转基因体细胞为供体细胞进行了核移植, 获得了能够体外发育的山羊转基因克隆胚胎, 体内成熟卵母细胞来源的核移植囊胚率为64.8%, 体外成熟卵母细胞来源的核移植囊胚率为51.7%, 证明了山羊转基因体细胞能够支持克隆胚的进一步发育。     

重组人SOD1/3转基因山羊的制备及表达产物的检测

设计了以hSOD1、hSOD3为编码序列,以山羊β-酪蛋白/CMV杂合启动增强子构建乳腺特异性表达载体rhSOD1、rhSOD3,共转染母山羊胎儿成纤维细胞,采用PCR和扩增产物序列分析筛选获得SOD1/3克隆细胞株,应用体细胞核移植(SCNT)制备双转基因山羊。出生小羊经PCR和扩增产物序列分析验证是否成功整合外源基因,经Western blotting、ELISA及体外活性检来验证分析表达产物。结果表明:获得SOD1/3转基因山羊胎儿成纤维细胞系6株;原代双转基因体克隆山羊1只(♀);从该转基因羊乳汁中检测到rhSOD1、rhSOD3,浓度分别为:88.81±8.36 mg/L和267.82±12.67 mg/L;转基因羊乳汁中重组人SOD酶活性为1 432±157 U/mL。研究表明,以双载体和单标记基因转染山羊胎儿成纤维细胞可获得双基因整合转基因细胞系,并且以SOD1与SOD3功能基因均可在山羊乳腺中共同表达,表达产物具有较好的生物学活性。     

ht-Pam基因在山羊β-酪蛋白基因座定位整合的研究

利用体细胞基因打靶与核移植技术制备动物乳腺生物反应器是当今转基因定位整合表达的一种新技术。分别克隆山羊的β-酪蛋白基因5′调控区的6.3kb片段,外显子7、外显子8和9三个基因片段,并与克隆的人tPA突变体cDNA一起构建了含有neo和tk正负筛选标记基因的β-酪蛋白基因打靶载体P^GBC4tPA,并验证了neo基因、tk基因以及Cre-LoxP系统的有效性。将线性化的P^GBC4tPA通过电转染整合到山羊胎儿成纤维细胞基因组中,利用G418和GANC进行抗性细胞克隆的药物筛选,初步获得抗性细胞克隆244个,PCR检测后获得阳性细胞克隆31个,其中初步验证2个细胞克隆转植基因整合位点重组后的基因序列正确,并且该细胞克隆能够有效扩增。这为下一步基因打靶体细胞核移植制备山羊乳腺生物反应器奠定了基础。     

Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells.

Lactoferrin inhibits cell proliferation and suppresses tumor growth in vivo. However, the molecular mechanisms underlying these effects remain unknown. In this in vitro study, we demonstrate that treatment of breast carcinoma cells MDA-MB-231 with human lactoferrin induces growth arrest at the G1 to S transition of the cell cycle. This G1 arrest is associated with a dramatic decrease in the protein levels of Cdk2 and cyclin E correlated with an inhibition of the Cdk2 kinase activity. Cdk4 activity is also significantly decreased in the treated cells and is accompanied by an increased expression of the Cdk inhibitor p21(CIP1). Furthermore, we show that lactoferrin maintains the cell cycle progression regulator retinoblastoma protein pRb in a hypophosphorylated form. Additional experiments with synchronized cells by serum depletion confirm the anti-proliferative activity of human lactoferrin. These effects of lactoferrin occur through a p53-independent mechanism both in MDA-MB-231 cells and other epithelial cell lines such as HBL-100, MCF-7, and HT-29. These findings demonstrate that lactoferrin induces growth arrest by modulating the expression and the activity of key G1 regulatory proteins.     

Inhibition of binding of lactoferrin to the human promonocyte cell line THP-1 by heparin: the role of cell surface sulphated molecules

Lactoferrin, an iron-binding protein of the transferrin family, is a highly basic protein which interacts with many acidic molecules, including heparin proteoglycans. Such interactions may modify some of the biological properties of lactoferrin. In the present work we found that heparin caused a dose-dependent inhibition of specific binding of both human and bovine lactoferrin to human monocytic THP-1 cells. Low-affinity binding sites (Kd 500 nM) were more susceptible to inhibition by heparin than the high-affinity sites (Kd 100 nM). The effect was mediated by interaction between lactoferrin and heparin rather than by competition between heparin and lactoferrin for common binding sites on the cells. Pretreatment of cells with NaClO3 to prevent sulphation of surface glycosaminoglycans reduced lactoferrin binding, and de-N-sulphated heparin did not inhibit binding of lactoferrin to THP-1 cells. These results suggest that heparin binding and monocyte/macrophage binding by lactoferrin both involve interactions between basic regions in the N1 domain of lactoferrin and sulphate groups. The N-terminal Arg2-Arg5 sequence of human lactoferrin may be involved, but it does not seem to be the key element in these interactions.     

Surface expression of lactoferrin by resting neutrophils

We examined the surface expression of lactoferrin by human neutrophils. Western blot analysis with anti-lactoferrin antibodies demonstrated the presence of a 78- to 79-kDa band in plasma membranes isolated from resting neutrophils that corresponded to the 78- to 79-kDa protein in neutrophil secondary granules. Flow cytometry using FITC-conjugated anti-lactoferrin antibodies confirmed that lactoferrin is expressed on the neutrophil surface. Preincubating the neutrophils in acidic (pH 3.9) buffer did not alter staining of the cells by the antibodies. Surface expression of lactoferrin was also detected on neutrophils in whole blood. Neutrophil activation by C5a or the calcium ionophore A23187 did not increase the surface expression of lactoferrin. Instead, the level of lactoferrin expression detected with one of two monoclonal antibodies was diminished after neutrophil activation, suggesting a possible conformational change in the lactoferrin. The surface-expressed lactoferrin may provide a mechanism for the interaction between lactoferrin-binding microorganisms and neutrophils.     

Hepatitis C virus envelope proteins bind lactoferrin.

Hepatitis C virus (HCV) has two envelope proteins, E1 and E2, which form a heterooligomer. During dissection of interacting regions of HCV E1 and E2, we found the presence of an interfering compound or compounds in skim milk. Here we report that human as well as bovine lactoferrin, a multifunctional immunomodulator, binds two HCV envelope proteins. As determined by far-Western blotting, the bacterially expressed E1 and E2 could bind lactoferrin in human milk directly separated or immunopurified and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The bindings of lactoferrin and HCV envelope proteins in vitro were confirmed by another method, the pull-down assay, with immunoprecipitated lactoferrin-bound protein A resin. By the same assay, mammal-expressed recombinant E1 and E2 were also demonstrated to bind human lactoferrin efficiently in vitro. Direct interaction between E2 and lactoferrin was proved in vivo, since anti-human lactoferrin antibody efficiently coimmunoprecipitated with secreted and intracellular forms of the E2 protein, but not glutathione S-transferase (GST), from lysates of HepG2 cells transiently cotransfected with the expression plasmids of human lactoferrin and gE2t-GST (the N-terminal two-thirds of E2 fused to GST) or GST. The N-terminal loop of lactoferrin, the region important for the antibacterial activity, has only a little role in the binding ability to HCV E2 but affected the secretion or stability of lactoferrin. Taken together, these results indicate the specific interaction between lactoferrin and HCV envelope proteins in vivo and in vitro.     

人乳铁蛋白基因克隆及细胞表达研究

通过PCR法直接克隆了2.366kb的人乳铁蛋白基因cDNA序列及800bp的山羊β乳球蛋白基因5′ 端调控序列,并连接到表达载体pLNCX中。利用脂质体包裹含人乳铁蛋白基因cDNA的重组质粒pLNCXHLF,并导入到小鼠乳腺癌细胞株MA∕782中,G418及PCR筛选获得阳性单克隆细胞,增殖后,转染细胞利用海藻酸钠固定化包埋培养,经激素诱导,培养液上清通过Western印记检测证明,转染细胞表达并分泌出人乳铁蛋白,分子质量为34kDa;ELISA法测出,每升培养基(含105个细胞)重组蛋白最高表达量为65mg;抗菌实验表明,所获得的重组人乳铁蛋白具有抑制大肠杆菌生长的作用,而且比人乳铁蛋白标准品作用更强。 Abstract:In this paper,we directly cloned 2.366Kb cDNA sequence of human lactoferrin gene and 800bp 5′flank regulatory sequence of β/lactoglobulin gene from goat by PCR,then connected them with the expression vector pLNCX.The recombinant plasmid pLNCXHLF containing human lactoferrin gene cDNA was transfected into mice mammary tumor cell line MA/782 after liposome transinfection.Positive single clone cells were selected with G418 and by PCR.After proliferating,the transfected cells immobilized and cultured in soldium alginate were induced by hormone.The result of Western blotting analysis on cultured cell supernatant shows that transfected cells can express the exogenic gene and secrete hLF protein,whose MW is 34 KD.The highest amount detected by ELISA reached 65mg/l medium/105 cells.The result of antibacterial experiment indicates that the recombinant hLF protein has the effect of inhibiting E.coli proliferation;moreover,its activity is superior to the commercial available hLF′s.     

Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autoperoxidation.

Human mononuclear phagocytes do not contain the iron-binding protein lactoferrin that we have previously demonstrated inhibits the potential for human neutrophils to generate hydroxyl radical in the presence of an exogenous iron catalyst of the Haber-Weiss reaction. Previous work by other investigators has suggested that mononuclear phagocytes (monocytes and monocyte-derived macrophages (MDM] have the capacity to bind exogenous lactoferrin via lactoferrin-specific membrane surface receptors. Accordingly, we examined the possibility that uptake of iron-free (apo) lactoferrin by human mononuclear phagocytes could play a role in limiting the potential for generation of hydroxyl radical during the monocyte/MDM respiratory burst. When monocytes or MDM were incubated in the presence of apo-lactoferrin, cell-associated lactoferrin increased in proportion to the concentration of lactoferrin provided. Similar results were obtained with iron-loaded (diferric) milk lactoferrin. Consistent with the in vivo importance of these findings, we found that lactoferrin was intimately associated with human alveolar macrophages obtained by bronchoalveolar lavage. The fucose polymer fucoidan inhibited lactoferrin uptake whereas exogenous transferrin or MDM exposure to IFN-gamma was without effect. Scatchard binding analysis confirmed the presence of a lactoferrin-specific receptor with a calculated kDa of 3.56 x 10(-6) M and 3.4 x 10(7) binding sites per cell. Subcellular fractionation studies indicated that twofold more of the lactoferrin which became cell-associated over the 1-h incubation time could be found in the cytoplasmic fraction compared to the plasma membrane-containing fraction, consistent with previous evidence by others for internalization of lactoferrin by mononuclear phagocytes. When lactoferrin-loaded monocytes/MDM were incubated in lactoferrin-free media, evidence for release of lactoferrin was obtained by SDS-PAGE and immunoblot analysis, suggesting the presence of a recyclable pool of cell-associated lactoferrin. To assess the impact of lactoferrin loading on monocyte/MDM hydroxyl radical formation, lactoferrin-loaded phagocytes were stimulated with PMA in the presence of catalytic iron. Hydroxyl radical generation by lactoferrin-loaded cells was decreased to about 50% of control cells. Similarly, monocytes that had been lactoferrin-loaded demonstrated a 28% decrease in autooxidation of their membrane when stimulated in the presence of catalytic iron. These data suggest that lactoferrin binding may play an important role in maintaining optimal mononuclear phagocyte function and protecting adjacent tissue from untoward phagocyte-associated hydroxyl radical generation.